 This is a Phase 1, single dose, open-label, sequential group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, non-hepatically impaired subjects. Primary objective: To evaluate the pharmacokinetics of a single oral dose of PA-824 in subjects with mild, moderate, and severe hepatic impairment as assessed by Child-Pugh score, relative to matched non-hepatically impaired subjects. Secondary objective: To evaluate the safety of a single oral dose of PA-824 in subjects with mild, moderate, and severe hepatic impairment as assessed by Child-Pugh score, relative to matched non-hepatically impaired subjects. 